Lars Björnebo

Publikationer
CV
Populärvetenskap och samverkan

Artiklar

Article: WORLD JOURNAL OF UROLOGY. 2023;41(11):2967-2974

Diagnosis of prostate cancer with magnetic resonance imaging in men treated with 5-alpha-reductase inhibitors.

Falagario UG; Lantz A; Jambor I; Busetto GM; Bettocchi C; Finati M; Ricapito A; Luzzago S; Ferro M; Musi G; Totaro A; Racioppi M; Carbonara U; Checcucci E; Manfredi M; D'Aietti D; Porcaro AB; Nordström T; Björnebo L; Oderda M; Soria F; Taimen P; Aronen HJ; Perez IM; Ettala O; Marchioni M; Simone G; Ferriero M; Brassetti A; Napolitano L; Carmignani L; Signorini C; Conti A; Ludovico G; Scarcia M; Trombetta C; Claps F; Traunero F; Montanari E; Boeri L; Maggi M; Del Giudice F; Bove P; Forte V; Ficarra V; Rossanese M; Mucciardi G; Pagliarulo V; Tafuri A; Mirone V; Schips L; Antonelli A; Gontero P; Cormio L; Sciarra A; Porpiglia F; Bassi P; Ditonno P; Boström PJ; Messina E; Panebianco V; De Cobelli O; Carrieri G; PROMOD Study Group
Article: JAMA NETWORK OPEN. 2023;6(9):e2332900

Biochemical Recurrence and Risk of Mortality Following Radiotherapy or Radical Prostatectomy.

Falagario UG; Abbadi A; Remmers S; Björnebo L; Bogdanovic D; Martini A; Valdman A; Carrieri G; Menon M; Akre O; Eklund M; Nordström T; Grönberg H; Lantz A; Wiklund P
Journal article: INVESTIGATIVE UROLOGY. 2023;209(Supplement 4):e419

PD15-04 PREDICTION OF PROSTATE CANCER SPECIFIC MORTALITY IN MEN UNDERGOING RADIOTHERAPY WITH OR WITHOUT HORMONAL TREATMENT, RISK STRATIFICATION BASED ON CLINICAL CHARACTERISTICS AND PSA TREATMENT RESPONSE

Falagario U; Bogdanovic D; Björnebo L; Abbadi A; Valdman A; Eklund M; Nordström T; Aly M; Grönberg H; Wiklund P; Lantz A
Journal article: INVESTIGATIVE UROLOGY. 2023;209(Supplement 4):e214

MP17-06 VALIDATION OF EAU RISK GROUPS FOR BIOCHEMICAL RECURRENCE AFTER RADIOTHERAPY AND RADICAL PROSTATECTOMY FOR PREDICTION OF PROSTATE CANCER MORTALITY

Falagario U; Bogdanovic D; Björnebo L; Abbadi A; Valdman A; Eklund M; Nordström T; Aly M; Grönberg H; Lantz A; Wiklund P
Journal article: EUROPEAN UROLOGY. 2023;83:s1613-s1614

Prediction of prostate cancer specific mortality in men undergoing radiotherapy with or without hormonal treatment, risk stratification based on clinical characteristics and PSA treatment response

Falagario UG; Bogdanovic D; Bjornebo L; Abbadi A; Valdman A; Eklund M; Nordstrom T; Aly M; Gronberg H; Wiklund P; Lantz A
Journal article: EUROPEAN UROLOGY. 2023;83:s379-s380

A0266 Validation of EAU Risk groups for biochemical recurrence after radiotherapy and radical prostatectomy for prediction of prostate cancer mortality

Falagario UG; Bogdanovic D; Björnebo L; Abbadi A; Valdman A; Eklund M; Nordström T; Aly M; Grönberg H; Lantz A; Wiklund P
Article: JAMA ONCOLOGY. 2022;8(7):1019-1026

Association of 5α-Reductase Inhibitors With Prostate Cancer Mortality.

Björnebo L; Nordström T; Discacciati A; Palsdottir T; Aly M; Grönberg H; Eklund M; Lantz A
Journal article: INVESTIGATIVE UROLOGY. 2022;207(Supplement 5):e991

MP58-03 PROSTATE CANCER SCREENING - A NOVEL RISK PREDICTION TOOL WITH STANDARD BIOPSIES VS. PSA WITH MRI-TARGETED BIOPSIES

Björnebo L; Discacciati A; Eklund M; Grönberg H; Lantz A; Nordström T
Journal article: INVESTIGATIVE UROLOGY. 2022;207(Supplement 5):e41

PD03-02 LONG-TERM EFFECTS OF 5Α-REDUCTASE INHIBITORS ON PROSTATE CANCER MORTALITY - A LARGE POPULATION-BASED PROSPECTIVE STUDY

Björnebo L; Nordström T; Discacciati A; Palsdottir T; Aly M; Grönberg H; Eklund M; Lantz A
Journal article: EUROPEAN UROLOGY. 2022;81:s561-s562

A0362 Long-term effects of 5α-reductase inhibitors on prostate cancer mortality: A large population-based prospective study

Björnebo L; Nordström T; Discacciati A; Palsdottir T; Aly M; Grönberg H; Eklund M; Lantz A
Journal article: EUROPEAN UROLOGY. 2022;81:s554-s555

A0358 Prostate cancer screening: A novel risk prediction tool with standard biopsies vs. PSA with MRI-targeted biopsies

Björnebo L; Discacciati A; Eklund M; Grönberg H; Lantz A; Nordström T
Article: WORLD JOURNAL OF UROLOGY. 2021;39(6):1797-1804

Predictors of adverse pathology on radical prostatectomy specimen in men initially enrolled in active surveillance for low-risk prostate cancer.

Björnebo L; Olsson H; Nordström T; Jäderling F; Grönberg H; Eklund M; Lantz A

Alla övriga publikationer

Conference publication: EUROPEAN UROLOGY. 2023;83:S379-S380

Validation of EAU Risk groups for biochemical recurrence after radiotherapy and radical prostatectomy for prediction of prostate cancer mortality

Falagario UG; Bogdanovic D; Bjornebo L; Abbadi A; Valdman A; Eklund M; Nordstrom T; Aly M; Gronberg H; Lantz A; Wiklund P
Letter: JAMA ONCOLOGY. 2022;:1852

Association of 5α-Reductase Inhibitor Use With Prostate Cancer-Specific Mortality-Reply.

Björnebo L; Eklund M; Lantz A
Review: INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES. 2022;23(14):7844

Are We Ready to Implement Molecular Subtyping of Bladder Cancer in Clinical Practice? Part 2: Subtypes and Divergent Differentiation.

Sanguedolce F; Zanelli M; Palicelli A; Ascani S; Zizzo M; Cocco G; Björnebo L; Lantz A; Landriscina M; Conteduca V; Falagario UG; Cormio L; Carrieri G
Review: INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES. 2022;23(14):7819

Are We Ready to Implement Molecular Subtyping of Bladder Cancer in Clinical Practice? Part 1: General Issues and Marker Expression.

Sanguedolce F; Zanelli M; Palicelli A; Ascani S; Zizzo M; Cocco G; Björnebo L; Lantz A; Falagario UG; Cormio L; Carrieri G
Conference publication: EUROPEAN UROLOGY. 2022;81:S561-S562

Long-term effects of 5α-reductase inhibitors on prostate cancer mortality: A large population-based prospective study

Bjornebo L; Nordstrom T; Discacciati A; Palsdottir T; Aly M; Gronberg H; Eklund M; Lantz A
Conference publication: EUROPEAN UROLOGY. 2022;81:S554-S555

Prostate cancer screening: A novel risk prediction tool with standard biopsies vs. PSA with MRI-targeted biopsies

Bjornebo L; Discacciati A; Eklund M; Gronberg H; Lantz A; Nordstrom T
Review: CELL COMMUNICATION AND SIGNALING. 2021;19(1):78

Role of α- and β-adrenergic signaling in phenotypic targeting: significance in benign and malignant urologic disease.

Archer M; Dogra N; Dovey Z; Ganta T; Jang H-S; Khusid JA; Lantz A; Mihalopoulos M; Stockert JA; Zahalka A; Björnebo L; Gaglani S; Noh MR; Kaplan SA; Mehrazin R; Badani KK; Wiklund P; Tsao K; Lundon DJ; Mohamed N; Lucien F; Padanilam B; Gupta M; Tewari AK; Kyprianou N

Anställningar

Doktorand, Medicinsk epidemiologi och biostatistik, Karolinska Institutet, 2020-2024

Examina och utbildning

Läkarexamen, Karolinska Institutet, 2022

Artiklar

Alla övriga publikationer

Anställningar

Examina och utbildning

Nyheter från KI

Kalenderhändelser från KI